StreetAlpha
Scribe Therapeutics, Inc. · Earnings

SCTX Earnings Results and History

Latest: Q3 2026From SEC 8-K, 10-Q and 10-K filings

Scribe Therapeutics, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.

← SCTX stock page

Q3 2026 result
Results are out
  • EPS−$0.68
  • Revenue–

Filed ยท Press release

Key takeaways

from the press release
  • Collaboration revenue fell to $1.6M from $1.9M in Q2, mainly on lower Eli Lilly reimbursable research activity.
  • Net loss widened to $9.9M, or $0.68 per share, from $6.5M in Q2, as G&A rose to $4.2M on stock compensation and public company costs.
3 more takeaways with a free account.Create free account

Filings and dates

SEC EDGAR

Also see SCTX institutional ownership and the earnings calendar.

SCTX earnings FAQ

What were SCTX's latest earnings?

For Q3 2026 Scribe Therapeutics, Inc. reported, GAAP EPS of -$0.68. The results were filed with the SEC on Nov 12, 2026.

When is SCTX's next earnings date?

There is no confirmed date on our calendar yet. Most companies report about four to six weeks after each quarter ends.

Where do these numbers come from?

Results, guidance and financials come from Scribe Therapeutics, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.